|Bid||6.03 x 500|
|Ask||6.51 x 500|
|Day's range||6.04 - 6.26|
|52-week range||4.60 - 11.72|
|PE ratio (TTM)||N/A|
|Earnings date||7 Mar 2018 - 12 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.75|
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aduro Biotech, Inc. (NASDAQ:ADRO), Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Gevo, Inc. (NASDAQ:GEVO), OSI Systems, Inc. (NASDAQ:OSIS), Senseonics Holdings, Inc. (NYSE:SENS), and Donnelley Financial Solutions Inc. (NYSE:DFIN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that it has completed enrollment in its Phase 3 study of 1404, a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. “The results of this large-scale Phase 3 study will provide important insights on the potential of our novel imaging agent to accurately and non-invasively detect and monitor patients with low-grade prostate cancer,” said Mark Baker, Chief Executive Officer of Progenics. The Phase 3 study enrolled approximately 450 patients in the U.S. and Canada with newly-diagnosed or low-grade prostate cancer, whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and/or are candidates for active surveillance.
Stocks that moved substantially or traded heavily Friday: Adtran Inc., down $2.90 to $19.35 The networking equipment maker gave weak revenue forecasts because a major customer is spending less. Bonanza ...
Shares of Progenics Pharmaceuticals Inc. surged 21% in premarket trade Friday, after the company said the U.S. Food and Drug Administration has accepted for review its new drug application for Azedra in ...
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for AZEDRA® in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors. The FDA granted Progenics’ request for Priority Review and has set an action date of April 30, 2018 under the Prescription Drug User Fee Act (PDUFA).
On a per-share basis, the New York-based company said it had a loss of 22 cents. The biopharmaceutical company posted revenue of $2.7 million in the period. Progenics shares have declined 32 percent since ...